$532.2 Million in Total Cash at Quarter End; Strong Balance Sheet Expected to Support Operations into Second Half of 2024
Additional Data from Adintrevimab Phase 2/3 STAMP Treatment Trial to be Presented at ASM Annual Meeting
WALTHAM, Mass., May 13, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases, today reported financial results for the quarter ended March 31, 2022.
“We continue to be encouraged by adintrevimab’s potential as a prophylactic and treatment option for certain variants of SARS-CoV-2, which is supported by the positive data that met all primary endpoints from our global EVADE and STAMP trials. We continue to engage with the FDA and are closely monitoring the evolution of the virus and the in vitro activity of adintrevimab against predominant variants in the U.S. to determine the optimal timing for an EUA request,” said David Hering, interim chief executive officer and chief operating officer of Adagio. “Our efforts to improve antibody activity to the Omicron variant are ongoing, including modifications to adintrevimab and exploring higher doses in our Phase 1 trial. Additionally, we are advancing efforts to develop next generation monoclonal antibodies and move appropriate candidate(s) into preclinical testing. With capital to fuel our operations into the second half of 2024, we are confident in the road ahead for both Adagio and adintrevimab as we aim to bring differentiated antibody solutions forward for infectious diseases.”
Publication in Science Immunology
Research conducted by Adagio’s chief scientific officer, among others, was recently published online in Science Immunology. The publication, entitled “Recall of pre-existing cross-reactive B cell memory following Omicron BA.1 breakthrough infection,” is the first to describe the antibody response induced by Omicron breakthrough infection in molecular detail.
Upcoming Oral Data Presentation
Adagio plans to present additional data from its global Phase 2/3 STAMP COVID-19 treatment trial of adintrevimab at the American Society for Microbiology annual meeting taking place June 9-13, 2022, in Washington D.C. Details of the oral presentation are as follows:
- Title: Preliminary Results from the Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Adintrevimab in the Treatment of Ambulatory Participants with Mild or Moderate COVID-19 (STAMP)
- Date & Time: Saturday, June 11, 2022, between 9:15-10:05 a.m. ET
First Quarter 2022 Financial Results
- Cash Position: Cash and cash equivalents were $532.2 million as of March 31, 2022.
- Cash Runway: Based on current operating plans, Adagio expects its existing total cash and cash equivalents will enable the company to fund its operating expenses into the second half of 2024.
- Research & Development (R&D) Expenses: R&D expenses were $92.0 million for the first quarter of 2022, compared to $34.0 million for the comparable period of 2021. These increases are attributable to manufacturing validation and supply activities and ongoing clinical trial expenses.
- Selling, General & Administrative (SG&A) Expenses: SG&A expenses were $8.7 million for the first quarter of 2022, compared to $3.7 million for the comparable period of 2021. These increases are attributable to higher expenses due to public company costs and personnel.
- Net Loss and Net Loss per Share: Net loss was $100.7 million for the first quarter of 2022, compared to $38.7 million for the comparable period in 2021. Basic and diluted net loss per share was $0.93 for the first quarter of 2022.
About Adintrevimab
Adintrevimab (ADG20), Adagio’s lead product candidate, is designed to be a potent, broadly neutralizing antibody for both the prevention and treatment of COVID-19, including disease caused by most variants. Adintrevimab is being assessed in two separate Phase 2/3 clinical trials: the EVADE trial for the prevention of COVID-19 in both the post-exposure and pre-exposure settings, and the STAMP trial for the treatment of COVID-19. Preliminary data from these trials demonstrated that in the pre-Omicron population, adintrevimab met the primary endpoints across all three indications, demonstrating statistically significant and clinically meaningful efficacy. Across each of the trials, intramuscular (IM) administration of adintrevimab at the 300mg dose had a similar safety profile to that of placebo. Adintrevimab is also being evaluated in a Phase 1 study to evaluate safety and pharmacokinetics at higher doses and, as of an interim data cut, no study drug related adverse events, serious adverse events, injection-site reactions or hypersensitivity reactions were reported across all dose levels evaluated. Adintrevimab is an investigational monoclonal antibody that is not approved for use in any country. The safety and efficacy of adintrevimab have not been established.
About Adagio Therapeutics
Adagio (Nasdaq: ADGI) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of differentiated products for the prevention and treatment of infectious diseases. The company is developing its lead product candidate, adintrevimab, for the prevention and treatment of COVID-19, the disease caused by the virus SARS-CoV-2 and its variants. Beyond COVID-19, Adagio is leveraging robust antibody discovery and development capabilities that have enabled expedited advancement of adintrevimab into clinical trials to develop therapeutic or preventative options for other infectious diseases, such as additional coronaviruses and influenza. Adintrevimab is an investigational monoclonal antibody that is not approved for use in any country. The safety and efficacy of adintrevimab have not been established. For more information, please visit www.adagiotx.com.
Cautionary Note Regarding Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “could”, “expects,” “intends,” “potential”, “projects,” and “future” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning, among other things, our plans and strategies related to our emergency use authorization (EUA) submission for adintrevimab; our plans to advance adintrevimab as a potential prophylaxis and treatment option for COVID-19, including disease caused by most variants; our plans for continued communications with the U.S. Food and Drug Administration; our ongoing research and development plans, including our efforts to evaluate higher doses of adintrevimab to improve efficacy against, and to modify adintrevimab to improve binding to, the Omicron variant and its lineages, including BA.1 and BA.2; our plans to develop therapeutic or preventative options for other infectious diseases, such as additional coronaviruses and influenza; the accuracy of the company’s estimates regarding expenses, capital requirements and needs for additional financing; the sufficiency of the company’s existing capital resources to fund its future operating expenses and capital expenditure requirements; and other statements that are not historical fact. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the results described in or implied by the forward-looking statements, including, without limitation: the impacts of the COVID-19 pandemic on our business and those of our collaborators, our clinical trials and our financial position; unexpected safety or efficacy data observed during preclinical studies or clinical trials; the predictability of clinical success of adintrevimab based on neutralizing activity in pre-clinical studies; variability of results in models used to predict activity against SARS-CoV-2 variants of concern; clinical trial site activation or enrollment rates that are lower than expected; changes in expected or existing competition; changes in the regulatory environment; and the uncertainties and timing of the regulatory approval process, including the outcome of our discussions with regulatory authorities concerning our Phase 2/3 clinical trials, whether adintrevimab is able to demonstrate activity against predominant SARS-CoV-2 variant(s) in the U.S., whether we are able to successfully submit an emergency use authorization in the future, and the outcome of any such emergency use application submission; whether research and development efforts will improve efficacy of adintrevimab against predominant variants or identify additional monoclonal antibodies for the prevention and treatment of COVID-19 and other infectious diseases; and whether we have adequate funding to meet future operating expenses and capital expenditure requirements into the second half of 2024. Other factors that may cause our actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the Securities and Exchange Commission (the “SEC”), and in our other filings with the SEC, and in Adagio’s future reports to be filed with the SEC. Such risks may be amplified by the impacts of the COVID-19 pandemic. Forward-looking statements contained in this press release are made as of this date, and Adagio undertakes no duty to update such information except as required under applicable law.
This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.
| Contacts Investor Contact: Monique Allaire, THRUST Strategic Communications monique@thrustsc.com | Media Contact: Dan Budwick, 1AB dan@1abmedia.com |
ADAGIO THERAPEUTICS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
(In thousands, except share and per share amounts)
| March 31, 2022 | December 31, 2021 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 532,220 | $ | 542,224 | ||||
| Marketable securities | — | 49,194 | ||||||
| Prepaid expenses and other current assets | 22,081 | 25,293 | ||||||
| Total current assets | 554,301 | 616,711 | ||||||
| Property and equipment, net | 87 | 83 | ||||||
| Operating lease right-of-use asset | 1,648 | — | ||||||
| Other non-current assets | 237 | 3,297 | ||||||
| Total assets | $ | 556,273 | $ | 620,091 | ||||
| Liabilities, Convertible Preferred Stock and Stockholders’ Equity (Deficit) | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 18,682 | $ | 5,783 | ||||
| Accrued expenses | 76,537 | 56,277 | ||||||
| Operating lease liability, current | 315 | — | ||||||
| Total current liabilities | 95,534 | 62,060 | ||||||
| Early-exercise liability | 3 | 6 | ||||||
| Operating lease liability, non-current | 1,344 | — | ||||||
| Other non-current liability | — | 6 | ||||||
| Total liabilities | 96,881 | 62,072 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders’ equity (deficit): | ||||||||
| Preferred stock (undesignated), $0.0001 par value; 10,000,000 shares authorized and no shares issued and outstanding at March 31, 2022 and December 31 2021 | — | — | ||||||
| Common stock, $0.0001 par value; 1,000,000,000 shares authorized, 109,675,173 shares issued and outstanding at March 31, 2022; 1,000,000,000 shares authorized, 111,251,660 shares issued and 110,782,909 shares outstanding at December 31, 2021 | 11 | 11 | ||||||
| Treasury stock, at cost; 0 shares and 468,751 shares at March 31, 2022 and December 31, 2021, respectively | — | — | ||||||
| Additional paid-in capital | 852,156 | 850,125 | ||||||
| Accumulated other comprehensive loss | — | (8 | ) | |||||
| Accumulated deficit | (392,775 | ) | (292,109 | ) | ||||
| Total stockholders’ equity (deficit) | 459,392 | 558,019 | ||||||
| Total liabilities, convertible preferred stock and stockholders’ equity (deficit) | $ | 556,273 | $ | 620,091 | ||||
ADAGIO THERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(UNAUDITED)
(In thousands, except share and per share amounts)
| Three Months Ended March 31, | Three Months Ended March 31, | |||||||
| 2022 | 2021 | |||||||
| Operating expenses: | ||||||||
| Research and development(1) | $ | 92,035 | $ | 34,032 | ||||
| Acquired in-process research and development(2) | — | 1,000 | ||||||
| Selling, general and administrative | 8,704 | 3,677 | ||||||
| Total operating expenses | 100,739 | 38,709 | ||||||
| Loss from operations | (100,739 | ) | (38,709 | ) | ||||
| Other income (expense): | ||||||||
| Other income (expense), net | 73 | 9 | ||||||
| Total other income (expense), net | 73 | 9 | ||||||
| Net loss | (100,666 | ) | (38,700 | ) | ||||
| Other comprehensive income (loss) | ||||||||
| Unrealized gain on available-for-sale securities, net of tax | 8 | — | ||||||
| Comprehensive loss | $ | (100,658 | ) | $ | (38,700 | ) | ||
| Net loss per share attributable to common stockholders, basic and diluted | $ | (0.93 | ) | $ | — | |||
| Weighted-average common shares outstanding, basic and diluted | 107,869,570 | — | ||||||
(1) Includes related-party amounts of $2,000 and $188 for the three months ended March 31, 2022 and 2021, respectively.
(2) Includes related-party amounts of $0 and $1,000 for the three months ended March 31, 2022 and 2021, respectively.
